Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. reports developments as a commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its recurring updates center on mitapivat, an oral pyruvate kinase activator marketed as PYRUKYND® and AQVESME™, including product revenue, U.S. and ex-U.S. commercialization, thalassemia approvals, and activity in pyruvate kinase deficiency, sickle cell disease, and other hemolytic anemias.
Company news also covers FDA interactions, supplemental application activity, conference presentations, and pipeline progress for tebapivat, a next-generation PK activator, and other rare disease programs. International commercialization themes include regulatory approvals and distribution activity in Gulf Cooperation Council markets through NewBridge Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ: AGIO) presented data at the 64th ASH Annual Meeting, highlighting the long-term efficacy and safety of PYRUKYND (mitapivat) in adults with pyruvate kinase deficiency. The data indicates sustained improvements in hemoglobin levels and reduced transfusion burdens over periods up to 38 months.
These findings support ongoing studies in pediatric populations, with expectations of similar benefits in children. PYRUKYND has been recognized as the first oral treatment for this rare disease with FDA and EMA approvals, enhancing Agios's position in hematology.
Agios Pharmaceuticals (NASDAQ: AGIO) is actively enrolling patients in its Phase 3 ENERGIZE and ENERGIZE-T studies evaluating PYRUKYND® (mitapivat) for adults with α- and β-thalassemia. The latest data presented at the 64th American Society of Hematology Annual Meeting demonstrated sustained improvements in hemoglobin concentrations and a well-tolerated safety profile for up to 72 weeks. Agios emphasizes the urgent need for new therapies for thalassemia, as current options are limited. An investor event will occur on Dec. 12, 2022, to discuss these developments further.
Agios Pharmaceuticals (Nasdaq: AGIO) announced the appointment of Tsveta Milanova as chief commercial officer, effective January 3, 2023. She will succeed Richa Poddar, who has held the position since 2016. Milanova brings over 20 years of experience in biopharmaceuticals, having worked at Alexion and Celgene. Her expertise in launching therapies for rare diseases is expected to enhance Agios' commercial strategy as the company seeks to expand its portfolio and market reach, particularly following the approval of its PK activator for adults with PK deficiency.
Agios Pharmaceuticals (NASDAQ: AGIO) will present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on December 7, 2022, at 11:25 a.m. ET. The presentation will be accessible via a live webcast on the company's website under the "Events & Presentations" section. A replay will be available for at least two weeks post-event. Agios focuses on therapies for rare diseases and is known for its first-in-class pyruvate kinase (PK) activator for adults with PK deficiency. The company is advancing its clinical pipeline for various hematological conditions.
Agios Pharmaceuticals has received EU marketing authorization for PYRUKYND® to treat pyruvate kinase (PK) deficiency in adults, marking it as the first disease-modifying therapy for this rare blood disorder. The approval follows positive results from pivotal studies, ACTIVATE and ACTIVATE-T, demonstrating significant clinical benefits, including increased hemoglobin levels and reduced transfusion needs. Agios aims to expand access via a global managed access program, and has plans to pursue further indications in pediatric patients and other diseases.
Agios Pharmaceuticals (NASDAQ: AGIO) presented significant clinical data at the 64th ASH Annual Meeting, highlighting the long-term benefits of PYRUKYND® in adults with Pyruvate Kinase (PK) deficiency. Results showed improved hemoglobin levels, reduced transfusion needs, and better patient-reported outcomes. Additionally, new findings for the investigational PK activator AG-946 support its Phase 2 study in Myelodysplastic Syndromes (MDS)-associated anemia. An investor event is scheduled for Dec. 12, 2022, at 7 a.m. ET to discuss these developments.
Agios Pharmaceuticals reported strong progress in Q3 2022, with net revenue of $3.5 million from the launch of PYRUKYND®, marking the second full quarter post-FDA approval. The company received a favorable opinion from the CHMP for PYRUKYND® to treat PK deficiency in adults and is on track for key enrollment milestones in pivotal studies. Leadership changes include the appointment of Cecilia Jones as CFO and new board members. As of September 30, 2022, Agios holds $1.0 billion in cash and marketable securities.
Agios Pharmaceuticals has sold its rights to a 5% royalty on U.S. net sales of TIBSOVO® to Sagard Healthcare Partners for $131.8 million. TIBSOVO® is FDA-approved for treating patients with the IDH1 mutation in acute myeloid leukemia and cholangiocarcinoma. Agios retains potential future payments related to vorasidenib, including a $200 million milestone and 15% royalties on U.S. net sales. This transaction enhances Agios' financial flexibility, aiding in the launch of PYRUKYND® and ongoing pivotal studies.
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on November 3, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and business updates. The webcast will be accessible on the company’s website in the Investors section and will be archived for later replay. Agios is recognized for its pioneering work in therapies for rare and genetically defined diseases, including a first-in-class pyruvate kinase activator for PK deficiency. The company continues to advance its clinical pipeline targeting various blood disorders.
Agios Pharmaceuticals has announced inducement equity awards for its new Chief Financial Officer, Cecilia Jones, effective September 26, 2022. The Board of Directors approved grants including a nonstatutory option to purchase 118,390 shares at an exercise price of $27.88, along with restricted stock units for 22,417 shares and performance stock units for 10,760 shares. Vesting is contingent on continued service, with a structured timeline over four years for the options and annually for the restricted stocks. This move aligns with Nasdaq Listing Rule 5635(c)(4).